Good morning and welcome to Markets Desk. Here is what is moving the needle right now.
The Bank for International Settlements, the central bank of central banks, is sounding a serious alarm in its annual report, warning that stretched equity valuations, investor complacency, and the AI-driven frenzy could trigger a sharp market correction with real spillover into credit markets. The BIS is essentially telling investors that circular financing patterns and frothy sentiment are a dangerous combination, and that the broader economy is not insulated from a sudden unwind.
On the deal front, French biopharmaceutical company Ipsen is acquiring clinical-stage biotech Kartos Therapeutics for four hundred fifty million dollars upfront, adding navtemadlin to its oncology pipeline. The move signals continued appetite for bolt-on acquisitions in the specialty pharma space, where companies are willing to pay premium prices for late-stage clinical assets rather than shoulder the full cost of internal development.
Shifting to the future of professional services, clients are now demanding that consulting firms put skin in the game by moving away from fixed fees toward outcome-based pricing models. The shift is being driven largely by AI transformation projects, where return on investment is genuinely uncertain, and clients are no longer willing to absorb all the risk while their advisors collect flat retainers regardless of results.
That is the tape. Markets Desk, signing off the floor.
